Repeated Epstein-Barr virus-associated hemophagocytic syndrome in a lupus nephritis patient

Clinical Nephrology

Volumn 77, Issue 1, 2012, Pages 71-74

  Miura, Shuhei ^a   Takeda, Kazuhito ^a   Muto, Yoshiharu ^a   Mukai, Hideyuki ^a   Furusho, Masahide ^a   Nakashita, Satsuki ^a   Maeda, Atsuhiro ^a   Kimura, Hiroshi ^a  

^a ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Cyclophosphamide; Epstein Barr virus; Hemophagocytic syndrome; Lupus nephritis; Real time PCR

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; FERRITIN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; PREDNISOLONE; STEROID;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; ENZYME BLOOD LEVEL; EPSTEIN BARR VIRUS; FATIGUE; FEMALE; FEVER; HEMOLYTIC ANEMIA; HEMOPHAGOCYTIC SYNDROME; HISTOLOGY; HUMAN; KIDNEY BIOPSY; LABORATORY TEST; NEPHROTIC SYNDROME; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; SEROLOGY; SORE THROAT; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; LUPUS NEPHRITIS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION;

EID: 84855447229     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106937     Document Type: Article

References (11)

1. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002; 44: 259-272.
2. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007; 48: 124-131.
3. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin Oncol. 1991; 18: 29-33.
4. Tsuda H. Hemophagocytic syndrome in children and adults. Int J Hematol. 1997; 65: 215-226.
5. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol. 1997; 66: 135-151.
6. Elazary AS, Wolf DG, Amir G, Avni B, Rund D, Yehuda DB, Sviri S. Severe Epstein-Barr virusassociated hemophagocytic syndrome in six adult patients. J Clin Virol. 2007; 40: 156-159.
7. Aouba A, De Bandt M, Aslangul E, Atkhen N, Patri B. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology. 2003; 42: 800-802.
8. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1992; 34: 945-950.
9. Belmont HM, Storch M, Buyon J, Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus. 1995; 4: 104-108.
10. Johnston A, Salles G, Espinouse D, Felman P, Andre P, Berger F, Coiffier B. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy. Clin Lymphoma Myeloma. 2008; 8: 356-358.
11. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005; 52: 501-513.